Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted August 14, 2007
Asking for evidence based results
Analysis of: FDA Adviser Questions Surrogate Endpoints for Diabetes Drug Approvals | www.medpagetoday.com
Author: GLG Member Program Contributor
The concept is great, but the delay in drug approval may make the effort not worth while for many companies.
Posted August 13, 2007
not always
Analysis of: Older and cheaper pills just fine for diabetes | www.reuters.com
Author: GLG Member Program Contributor
1-diabetics are an extremely diverse group of people 2-co-morbidities, stage of disease, and the pancreatic reserve all govern the ideal regimen for a certain patient 3-the more options we have, the better equipped we are to help more patients 4-glycemic control is not the only decisive factor when...
Posted August 9, 2007
Don't stop your statins now...
Analysis of: Taking statins may increase cancer risk | www.timesonline.co.uk
Author: GLG Member Program Contributor
Certainly, we've had a flurry of bad press over the last few years on blockbuster drugs that had unexpected consequences - Celebrex, ESAs (Epogen, Aranesp, etc...), and most recentlyl Avandia. Statins are some of the most widely used drugs in medicine in a multi-billion dollar industry. We know these...
Donald Fleming Posted August 9, 2007
Is it less or more cancer with statins?
Analysis of: Taking statins may increase cancer risk | www.timesonline.co.uk
Author: Donald Fleming, Division Head of Hematology and Oncology Davis Health System, Inc.
Statins have recent reputation as cancer promoting. Statins also have demonstrated benefit in treating cancer patients Statins can be eliminated based on the first issue
Posted August 9, 2007
Bringing up old concerns
Analysis of: Taking statins may increase cancer risk | www.timesonline.co.uk
Author: GLG Member Program Contributor
This was a retrospective analysis. The use of statins clearly show benefit and decreased mortality in  the number 1 killer of Americans-cardiovascular disease. It is still unclear, and this study highlights this, that there may be a threshold level which we should not  surpass....
Posted August 9, 2007
Yet Another Example of Why Physicians Should Wait to Prescribe New Drugs
Analysis of: Survey Report: Future May Be Bleak for Rosiglitizone (Avandia) | www.medpagetoday.com
Author: GLG Member Program Contributor
- rosiglitazone was marketed as being cardioprotective in patients   with type II diabetes - who are already at significant risk for   cardiac events - post-release research has shown that rosiglitazone actually increases   the risk of cardiac events by almost 50% - expect it to be off...
Posted August 9, 2007
Don't stop your statins now...
Analysis of: Taking statins may increase cancer risk | www.timesonline.co.uk
Author: GLG Member Program Contributor
Certainly, we've had a flurry of bad press over the last few years on blockbuster drugs that had unexpected consequences - Celebrex, ESAs (Epogen, Aranesp, etc...), and most recentlyl Avandia. Statins are some of the most widely used drugs in medicine in a multi-billion dollar industry.   ...
Posted August 8, 2007
Too early to tell
Analysis of: Taking statins may increase cancer risk | www.timesonline.co.uk
Author: GLG Member Program Contributor
An interesting association, but clearly NO cause and effect. This should be looked at prospectively. The benefits noted from statins are definitive.
Posted August 1, 2007
Per Quest, commonly used technology for the assay.
Analysis of: Quest Diagnostics Announces New Testing Technique For Improved Diagnosis Of Metabolic And Nutritional Disorders | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Per Quest's own website, their assay uses an existing technology employed by metabolic labs across the country (e.g. nothing new, nor obviously innovative in what they're marketing). They may be able to generate business from smaller hospitals/practices that don't have ready access to a local metabolic...
Posted August 1, 2007
Too little too late
Analysis of: FDA reviewer : Pull Avandia from shelves | www.chicagotribune.com
Author: GLG Member Program Contributor
Despite the FDA not pulling Avandia from the market, it seems that with the legal landmine that physicians practice in, many will be hard pressed to use the drug. One will have  to asses cardiac risk, and all diabetics are already felt to have the same risk as someone who has already had a heart...
Previous Page : 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Next211 to 220 of 373

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617